Member Info for guru121

it seems there is a demand for the shares.

50000-5000

has become very interesting.

not really,market already knew that and had taken that into consideration.hopefully things will pick up in few months time.rns is optimistic about the future.

sold @ 5.75

Contract with Swiss Health Insurer Share this article Print Alert TIDMAVIA Avia Health Informatics PLC 28 March 2012 Avia Health Informatics Plc ("Avia" or the "Company") Odyssey TeleAssess contract with Swiss Health Insurer Avia (AIM: AVIA), the developer and provider of decision support and clinical communication systems, is pleased to announce that has agreed the supply and implementation of Odyssey TeleAssess licences with a new client in Switzerland, a health insurance group that is about to launch new telehealth services. As the service does not go live until later in the year, the name is witheld for commercial reasons. This is the third client in Switzerland to adopt the latest .NET version of the company's pre-diagnostic clinical decision support software, Odyssey TeleAssess. Although the initial value of the contract is modest in relation to total turnover, it is strategically important for the company which expects further gains from Switzerland in the future, utilising the German, French and Italian translations of its extensive clinical content. Barry Giddings, Chairman of Avia Health Informatics Plc, commented: "We are excited to have secured another sale in Switzerland, which is an important marketplace for health IT. We are also looking forward to working with and supporting our new client in the set-up of their new call centre operation."

thanks for the enlightenment.

lol.on a serious note,why r u addicted to mouchel?

http://www.barchart.com/snapopinion/stocks/MCHL.LS

Mouchel appointed to HS2 framework 10 February 2012 High Speed Two (HS2), the company set up by the Department of Transport to develop and promote the new £32bn high-speed rail link between London, Birmingham, Leeds and Manchester, has awarded infrastructure and business services Group, Mouchel's engineering and environment business a place on its land referencing services framework. The initial plan is for a new railway line between London and the West Midlands, carrying 400m-long (1,300ft) trains at speeds of up to 250mph - faster than any current operating speed in Europe. Following the consultation for this first phase in 2011, HS2 has confirmed that work will now begin on the engineering, design and environmental aspects. Mouchel's role is to identify potentially affected properties and the legal interests of the owners/occupiers of these properties. This information is then delivered as a package to HS2 in support of the hybrid Bill it is developing that - once approved by Parliament - will authorise the scheme to be built and operated. Ashley Parry Jones, Mouchel's Divisional Director for Environment and Engineering, said: "Mouchel is the single largest supplier of these services in the UK, having worked on Crossrail, Thameslink, HS1 and Thames Tunnel. We are looking forward to supporting HS2 on this important programme." Work under the land reference services framework, which includes four companies, is valued at between £15m-£30m.

thats what i call do it like a man.buy 1,047,253 @ 99k.the stage is being set.

IF it were to be taken over in its current debt laden state,...it would probably be asset stripped..(that's what I would do from a business perspective....)...however, when they finaly agree a fiscal stimulus of some description, this will enhance it's value as a going concern and increase its viability as a good turn-around prospect...and at this point strongly increases it's venerability as a target....and if any one is going to make a move, they'd play their cards at this point...before it's valuation increases...and the next set of numbers. The takeover attempts by other parties in the previous TWO years has been very disruptive, not only to the clients, but also the company as well...this, currently , is now behind them. Allow Shearer to do his work and turn this around.....ps..(I still can't get my head around the fact that they turned down 135p a share.....with directors piling in at circa 75p a share after the rejection...and yet the share price is now languishing at these levels....a couple of 'director buys' at this level would do wonders for the valuation) With February now upon us...I expect some good rns's by the end of the month...(all my opinion of course)...interesting times ahead.

this will end up part of Costain, they have the backing to snap this up and refinance immediately bringing big gains with it... From their 5th Jan tu. Financial position There has been no material change in the financial position of the Group, which has a strong cash position of in excess of GBP100 million and no significant borrowings. Recently, the Group has further enhanced and extended its contract bonding and banking facilities with its relationship banks and surety companies. The facilities were increased by GBP30 million to GBP465 million and extended by two years to September 2015. These facilities ensure the Group has the necessary financial resources to capitalise on market opportunities as they arise and achieve its medium term objectives.

rns clearly states the company is in takeover mode, hence todays disclosure by darren freemantle.it may lead to an offer it may not.

2 points of interest.the company is in offer period hence the disclousre by todays rns.my source has informed me that more contracts are on the way.renewals r coming through NHS.

Market cap of less than a million now and with the Directors expect to record revenues for the 12 months to 31 March 2012 in the range of GBP2.2 million to GBP2.5 million. new contract with the nhs announced on monday. PathFinderRF sales now commenced Reduced cost by £350k in 2011 Further contracted cost reduction of £100k from March 2012 Creditor management including salary deferment of £200k in 2011, now reduced to less that £75k, forecast to reduce to zero by March 2012

To fully secure the development of the business, the directors do believe that at least £0.5m net cash will be required in 2012. This investment can of course come by way of a number of financial instruments or third party partnerships. The directors are actively pursuing all possible routes that may be available to them.The directors have prepared forecast information for the period to January 2013. The forecasts indicate that the Group`s revenues are expected to exceed costs due to 1) a reduction in development and salary costs, and 2) the introduction of new products and cloud services into existing and new markets, particularly in relation to Pathfinder.

Current background The financial and trading condition of the company rapidly deteriorated in the first quarter of the year April/June 2011. In early August 2011 based on the latest market intelligence a short term cash flow forecast was produced reflecting an immediate shortfall in cash through August and September 2011. In early August the directors, based on this forecast, requested a suspension in trading the company`s shares on AIM. Since 4 August 2011 the directors have been meeting on a weekly basis for a trading update and the cash position has been reported and monitored closely. On 24 August the directors announced short term bridging funding from its staff.

Whilst the market conditions remain difficult, Avia made inroads into both its traditional and targeted new markets of GP practices, walk-in centres and prisons/detention centres with year on year growth. Technical and clinical innovation has delivered a range of products that enabled the UK sales team to diversify from its traditional base into new areas. The Company secured a number of key UK 3-year customer contracts with both new and long-term customers, including sales of Odyssey Reception, Odyssey TeleAssess, and Odyssey FaceToFace, so consolidating its position within the UK. It also secured its first sale of Odyssey FirstAssess within the prison service.

The challenging market conditions experienced in our core UK markets over the period remained and continued through into the current year, restraining UK growth. However, we are now experiencing new sales from PathFinderRF in the final Quarter of the year and anticipate interest from the Care Home sector with our recent announcement of CareAssess via the cloud as a service. In addition we also anticipate interest from the GP market for Odyssey PatientAssess and Odyssey Reception.